Floatz logo

Binimetinib

Low-grade Serous Fallopian Tube Cancer

PfizerSmall moleculePhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Low-grade Serous Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
NRG Oncology
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Ohio State University Comprehensive Cancer Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 39 →

Same molecule, other indications

Binimetinib is also rated in:

metastatic malignant neoplasm in the colonDormant
BB
Indicative ·
70 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →